Member Info for Morgank

Remarkable recovery in SP, good news coming

Key comments from RNS
Separately, we remain on track to achieve the first ever FDA product clearance, the gold standard for medical devices globally, for a system to harvest cancer cells from patient blood for subsequent analysis, initially in metastatic breast cancer. Ongoing and constructive dialogue with FDA continues and a regulatory decision from FDA is awaited."

Angle PLC Update on lab accreditation and ovarian study

Source: UK Regulatory (RNS & others)
TIDMAGL

RNS Number : 2810Y

Angle PLC

13 January 2022

Many late reported large trades

Angle PLC Insight into drug resistance in NSCLC

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

10 January 2022

Nice to see confidence

Yes something going on , large share buys, options taken up, nearing all time high, end of year luming

Angle PLC Participation at Jefferies healthcare conference

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

12 November 2021


For immediate release 12 November 2021

ANGLE plc ("the Company")

PARTICIPATION AT JEFFERIES LONDON HEALTHCARE CONFERENCE

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that Andrew Newland, Chief Executive Officer, and Ian Griffiths, Chief Financial Officer, will be presenting at the Jefferies London Healthcare Conference on Tuesday 16 November at 10.00 AM GMT. This is the largest healthcare-dedicated investor conference in Europe.

Extract ..
Angle PLC Participation at Jefferies healthcare conference

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

12 November 2021


For immediate release 12 November 2021

ANGLE plc ("the Company")

PARTICIPATION AT JEFFERIES LONDON HEALTHCARE CONFERENCE

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that Andrew Newland, Chief Executive Officer, and Ian Griffiths, Chief Financial Officer, will be presenting at the Jefferies London Healthcare Conference on Tuesday 16 November at 10.00 AM GMT. This is the largest healthcare-dedicated investor conference in Europe.

Angle PLC Issue of Equity

Source: UK Regulatory (RNS & others)
TIDMAGL

RNS Number : 0082S

Angle PLC

10 November 2021


For immediate release 10 November 2021

ANGLE plc

("ANGLE" or the "Company")

Issue of Equity

Exercise of Options and Total Voting Rights

ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 31,666 new ordinary shares of GBP0.10 each ("New Ordinary Shares") in the Company. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

An application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted. to trading on AIM ("Admission") and it is expected that Admission will become effective, and trading will commence at 8.00 a.m. on 16 November 2021. Following Admission, the total number of Ordinary Shares in issue, and therefore the total number of voting rights, will be 234,973,717.

Closed up 4.6% @ 125 , maybe an RNS tomorrow

Looks like news is filtering through SP moving up since US market has opened

Angle PLC Change of Adviser

Source: UK Regulatory (RNS & others)
TIDMAGL

RNS Number : 9909Q

Angle PLC

02 November 2021


For immediate release 2 November 2021

ANGLE plc ("the Company")

Change of advisers

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointments of Berenberg as its Nominated Adviser and Joint Broker and Jefferies as its Joint Broker with immediate effect.

8,000,851,478
kilometers travelled, well done Seeing Machines

Thu, 30th Sep 2021 07:00

RNS Number : 4550N
Angle PLC
30 September 2021

For Immediate Release 30 September 2021


ANGLE plc

("ANGLE" or "the Company")



Interim Results for the six months ended 30 June 2021

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 30 June 2021 on Thursday 30 September 2021.

Angle PLC Parsortix demonstrates ability to isolate CTCs

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

27 September 2021


For immediate release 27 September 2021

ANGLE plc ("the Company")

Parsortix system demonstrates ability to isolate CTCs for downstream gene analysis revealing multiple prognostic biomarkers

Leading European study centre presents results of three studies in ovarian and lung cancer at 5(th) ACTC Conference

Novel CTC biomarkers found to predict progression free survival and treatment response for longitudinal patient monitoring in ovarian cancer

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Molecular Oncology Group at the Medical University of Vienna, presented results of three studies at the 5(th) Advances in Circulating Tumour Cells (ACTC) conference, held 22-25 September in Kalamata, Greece.

Angle PLC Study shows use of Parsortix to assess PD-L1

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

22 September 2021


For immediate release 22 September 2021

ANGLE plc ("the Company")

STUDY DEMONSTRATES USE OF PARSORTIX TO ASSESS PD-L1 STATUS OF CTCs IN NON-SMALL CELL LUNG CANCER PATIENTS WITH A SIMPLE BLOOD TEST

Further evidence supporting ANGLE's decision to develop a Parsortix-based PD-L1 assay to assess patient cancer PD-L1 status

ANGLE PD-L1 assay to be offered for use in cancer drug trials to pharma services customers developing new immunotherapy drugs

Angle PLC Parsortix enables gene expression analysis in mPCa

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

20 September 2021


For immediate release 20 September 2021

ANGLE plc ("the Company")

PARSORTIX SYSTEM ENABLES GENE EXPRESSION ANALYSIS IN METASTATIC PROSTATE CANCER PATIENTS

Parsortix able to isolate CTCs in 80% of patients providing access to tumour material for gene expression analysis when tissue biopsy not feasible

Longitudinal patient monitoring using Parsortix showed reduction in CTCs with patient drug response providing further evidence to support the use of Parsortix in pharma services business

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Medical University of Innsbruck, Austria has published results from a study in metastatic prostate cancer (mPCa) patients. A key aim of this study was to demonstrate the ability to analyse gene expression in circulating tumour cells (CTCs), which may help guide treatment decision-making for a diverse range of mPCa patients with differing tumour burdens and various prior therapies.

Vol figures can’t be correct if 6m cancelled